Supplemental viral disease — not on WHO NTD list.
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Vector & transmission control
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Aedes / Haemagogus vector control | Vector control | Approved | Urban & sylvatic transmission reduction | WHO yellow fever |
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Yellow fever 17D vaccine | Vaccine | Approved | Live attenuated; single dose lifelong immunity in most | WHO EML |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Supportive care (avoid aspirin/NSAIDs) | Supportive | Approved | No specific antiviral; hepatorenal support | WHO EML / standard of care |
| Liver failure & hemorrhage management | Supportive | Approved | Severe viscerotropic disease | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Post-vaccine adverse event monitoring | Surveillance | Approved | Rare YEL-AND / YEL-AVD after vaccination | WHO |
Associated drug targets (Open Targets): —
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0020502 · Updated 2026-07-10. Associations, not a diagnostic test.
Generated by OSMF NTD Intelligence Pipeline · Open Source Medicine Foundation